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Abstract 
Background: Glycans play critical roles in a number of biological activities. Two common types of glycans, N-linked 
and O-linked, have been extensively analyzed in the last decades. N-glycans are typically released from glycoproteins 
by enzymes, while O-glycans are released from glycoproteins by chemical methods. It is important to identify and 
quantify both N- and O-linked glycans of glycoproteins to determine the changes of glycans.
Methods: The effort has been dedicated to study glycans from ovarian cancer cells treated with O-linked glycosyla-
tion inhibitor qualitatively and quantitatively. We used a solid-phase chemoenzymatic approach to systematically 
identify and quantify N-glycans and O-glycans in the ovarian cancer cells. It consists of three steps: (1) immobilization 
of proteins from cells and derivatization of glycans to protect sialic acids; (2) release of N-glycans by PNGase F and 
quantification of N-glycans by isobaric tags; (3) release and quantification of O-glycans by β-elimination in the pres-
ence of 1-phenyl-3-methyl-5-pyrazolone (PMP).
Results: We used ovarian cancer cell lines to study effect of O-linked glycosylation inhibitor on protein glycosyla-
tion. Results suggested that the inhibition of O-linked glycosylation reduced the levels of O-glycans. Interestingly, it 
appeared to increase N-glycan level in a lower dose of the O-linked glycosylation inhibitor. The sequential release and 
analyses of N-linked and O-linked glycans using chemoenzymatic approach are a platform for studying N-glycans and 
O-glycans in complex biological samples.
Conclusion: The solid-phase chemoenzymatic method was used to analyze both N-linked and O-linked glycans 
sequentially released from the ovarian cancer cells. The biological studies on O-linked glycosylation inhibition indicate 
the effects of O-glycosylation inhibition to glycan changes in both O-linked and N-linked glycan expression.
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Background
Glycosylation is one of the most abundant and diverse 
protein modifications. It plays essential roles in the bio-
logical and physiological functions of a living organism 
[1]. Aberrant glycosylation is associated with different 
diseases, e.g. prostate cancer [2], ovarian cancer [3, 4], 
rheumatoid arthritis [5], diabetes [6], and cardiac dis-
eases [7, 8]. Studies reveal that cancer cells often display 
their glycans at different levels of structures as compared 
to those observed on normal cells [9]. Glycosylation can 
thus be harnessed for defining cancer malignancy and 
disease progression [10, 11]. The abnormal glycosylation 
may contribute to cancer metastasis [12, 13]. Therefore, it 
is important to characterize protein glycosylation in bio-
logical and clinical specimens.
The N-linked and O-linked glycans are two most com-
monly studied glycoforms in protein glycosylation. The 
N-glycan has common core structure (GlcNAc2Man3) 
that conjugates to the asparagine (Asn or N) residues in 
the consensus peptide motif of Asn-X-Ser/Thr [where 
X is any amino acid except proline (Pro)]; The O-glycan 
conjugates to serine (Ser) or threonine (Thr) without a 
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consensus amino-acid motif. The structure of glycans is 
complex due to its non-template biosynthesis pathway. 
The complexity is predominantly due to its variable mon-
osaccharides, branches, linkages, and isomers.
It is preferable to analyze both N-glycans and O-gly-
cans from glycoproteins; technology development to 
achieve this goal has been the focus for glycomics [14–
20]. Release of these glycans from glycoproteins can be 
fulfilled by enzymes or chemical reactions. PNGase F 
(peptide: N-glycosidase F) releases all N-glycans except 
for glycans with core-α(1,3)-fucose that are found only 
in slime molds, plants, insects, and parasites plant and 
insect [21], whereas PNGase A (peptide-N4-(N-acetyl-
β-glucosaminyl)asparagine amidase) releases these 
N-glycans  from glycopeptides including core-α(1,3)-
fucose and all N-glycans released by PNGase F [22]. 
However, no universal O-glycosidase has been devel-
oped for the removal of all O-glycans except for core 1 
(Gal-GalNAc) or core 3 (GlcNAc-GalNAc). The removal 
of O-glycans is usually performed through alkali treat-
ment using β-elimination [23, 24] or hydrazinolysis [25, 
26]. Chemical release is cost-effective and can be ubiq-
uitously applied to release different types of glycans. 
Hydrazine hydrolysis releases both O-glycans (60  °C) 
and N-glycans (95  °C) [26, 27]. However, even at a rela-
tively lower temperature for O-glycans release (60 °C), it 
can still result in N-glycan release. The recently reported 
oxidative strategy releases all types of glycans including 
N-glycans and O-glycans without specificity [28]. It has 
been reported that O-glycans can be specifically released 
at a mild β-elimination such as ammonia [29]; however, 
others showed that ammonia (26–28%) alone could also 
release both N-glycans and O-glycans [14]. Additional 
consideration with glycans released by the chemical 
methods is the sequential degradation of reducing-end 
monosaccharide units by consecutive β-elimination, also 
known as “peeling” [30, 31]. The peeling of the alditols on 
the reducing end is showed to be prevented by release of 
O-glycans in a mild medium in the presence of reagents 
for alditol capping [32]. Several chemical compounds 
have been exploited for the capping of O-glycan alditol 
after β-elimination. Among them, pyrazolone derivatives 
have been used for capping the alditol and enhancing 
hydrophobicity of glycans for LC–ESI–MS [33, 34].
An integrated platform has been sought for the com-
prehensive profiling of glycans [16–20, 35]. Numerous 
N-glycan studies have shown that native sialic acid resi-
dues are fragile and may be easily lost during sample 
preparation and ionization in MALDI-MS [14, 36–38]. 
Stabilization by chemical methods such as amidation 
[37], methyl esterification [39], permethylation [18, 19, 
40], and perbenzolylation [41] has been developed for 
analysis of sialylated glycans. For example, glycoproteins 
are systematically analyzed by immobilizing on poly-
mer membranes for sequential release of N-glycans and 
O-glycans [35]. Structural analysis can be achieved via 
sialidases or exoglycosidases in coupling with porous 
graphitized liquid chromatography-mass spectrometry 
[18]. Mass spectrometric screening strategy is devel-
oped for characterizing glycan component of both gly-
cosphingolipids and glycoproteins from a single sample 
[20]. These methods have been widely used for analysis of 
glycans in biological specimens, such as ovarian cancers 
from serum and cell lines [4, 42–44].
It has been successfully demonstrated that sialic acid 
residues can be effectively stabilized using an in-solution 
amidation [37, 45]. Permethylation of the released gly-
cans can protect sialic acids for both N- and O-glycans 
[46, 47]. Yet, the decomposition of O-acetyl groups may 
occur under the harsh conditions used for permethyla-
tion [45]. Besides, the permethylated glycans may lose 
their reactivity on the reducing-ends, consequently pre-
venting their further use for fluorophore, chromophore, 
or isobaric tag labeling [48]. To this end, we recently 
developed a solid-phase chemoenzymatic platform 
termed as glycoprotein immobilization for glycan extrac-
tion (GIG) by conjugating glycoproteins on solid phase, 
protecting sialic acids, and sequentially releasing N- and 
O-linked glycans for MS analyses [14, 49, 50].
Glycoprofiling on ovarian cancer serum found that 
unique N-glycans were present in cancer patient [4]. 
Profiling of N-glycans by a nanoLC mass spectromet-
ric method observed up-regulation of the fucosylated 
N-glycans in healthy controls [51]. Recent works discov-
ered the glycosylation changes in ovarian cancers were 
influenced by aberrant regulation of gene expression. 
The characteristic glycan features that were unique to 
the ovarian cancer membrane proteins have been iden-
tified, including “bi-secting N-acetyl-glucosamine” and 
“N,N′-diacetyl-lactosamine” type N-glycans [42]. These 
glycosylation changes in ovarian cancer may contribute 
to disease pathogenesis [44]. Therefore, inhibition of pro-
tein glycosylation may be useful for ovarian cancer treat-
ment. In this study, we applied the quantitative glycomics 
to the analyses of both N- and O-linked glycans in ovar-
ian cancer cells in the presence and absence of inhibitor 
for O-linked glycosylation. The glycosylation changes on 
both N-glycans and O-glycans are described.
Experimental section
Reagents and sample preparation
All chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO) unless specified otherwise. Aminolink resin, 
spin columns (snap cap), and Zeba spin desalting col-
umns were purchased from Life Technologies (Grand 
Island, NY). Alltech Extract-Clean Carbograph columns, 
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analytical column [NanoViper, 75  μm (ID), 150  mm, 
2  µm particle size], water, methanol, and acetonitrile 
(ACN) (HPLC grade) were purchased from Fisher Sci. 
(Waltham, MA). NaCl solution (5 M) was ordered from 
ChemCruz Biochemicals (Santa Cruz, CA). Chloroform 
was purchased from J.T. Baker (VWR, Radnor, PA). Cell 
lysis buffer consists of 1× PBS, 1% NP-40, 0.5% sodium 
deoxycholate (C24H39NaO4), 0.1% SDS, 2  mM EDTA, 
and 50 mM NaF. Micro-centrifuge tubes (1–2 mL) were 
purchased from Denville Scientific Inc. (Holliston, MA). 
Sep-Pak C18 1 cc Vac Cartridges (50 mg sorbent per car-
tridge, 55–105  μm particle size) were purchased from 
Waters Corporation. Peptide-N-glycosidase F (PNGase 
F), denaturing buffer (10×), and GlycoBuffer (G7; 10×) 
were from New England Biolabs (Ipswich, MA).
OVCAR‑3 cell culture and treatment
OVCAR-3 cell line (ATCC® HTB-161TM) was purchased 
from ATCC (American Type Culture Collection). Cell 
culture was proceed according to ATCC protocol. The 
culture medium consists of RPMI-1640 (Thermo Fisher), 
0.01 mg/mL bovine insulin (Sigma), and 20% fetal bovine 
serum (Sigma). OVCAR-3 cells were suspended in a 
15-cm cell culture dish (Thermo Fisher). O-GalNAc 
inhibitor (Benzyl-α-GalNAc or BAG; Sigma) was dis-
solved in DMSO (Dimethyl sulfoxide; Sigma) (100 mM). 
A final concentration of BAG (0, 0.2, 1, 2 mM) was added 
to OVCAR-3 for 24-h treatment. Cells were washed by 
1× PBS three times before harvest in 1.5 mL microcen-
trifuge tube, followed by cell lysis in 500 μL of 1× bind-
ing buffer. Protein concentration was determined by BCA 
assay (Thermo Fisher). One mg protein was used for gly-
can analysis.
Protein immobilization on solid phase and N‑glycan 
release
Proteins were first extracted from cells using cell lysis 
buffer. Proteins (1  mg) were denatured at 100°C for 
10 min in 100 μL solution consisting of 10 μL 10× dena-
turing buffer and 90 μL deionized (DI) water. After Ami-
nolink resin was pre-conditioned by 1× binding buffer 
(500 μL; 3×) (pH 10; 100 mM sodium citrate and 50 mM 
sodium carbonate) [52], the denatured proteins were 
mixed with resin in a spin column by adding 350 μL DI 
water and 50  μL 10× binding buffer. The reaction pro-
ceeded up to 4 h with mixing at room temperature, fol-
lowed by incubation for another 4 h after adding 25 μL 
of 1  M NaCNBH3. Next, resin was rinsed using 500  μL 
1× PBS (3×) (Thermo Fisher). The conjugation contin-
ued for 4 h in 500 μL 1× PBS in the presence of 50 mM 
NaCNBH3. The active aldehyde sites on the resin were 
blocked using 500  μL 1× Tris–HCl (50  mM NaC-
NBH3). After washing the resin using 1 M NaCl and DI 
water (500 μL, 3×), the sialic acid residues were reacted 
with 1  M p-Toluidine (pT, Sigma) buffer via carbodiim-
ide coupling (3  h). The pT buffer (465  μL) consisted of 
400 μL of 1 M pT, 25 μL HCl (36–38%), and 40 μL EDC 
(N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide). To 
remove chemical compounds such as pT and EDC, the 
resin was extensively washed with four solutions (500 μL) 
in a sequential order of 10% formic acid (3×), 10% ace-
tonitrile in 0.1% TFA (trifluoroacetic acid) (3×), 1  M 
NaCl (3×), and DI (3×). N-glycans were then enzymati-
cally released by 2 μL PNGase F (1000 units; 360 μL DI, 
40 μL 10× GlycoBuffer; 37 °C, 3 h). The released N-gly-
cans were purified by Carbograph as described in our 
previous protocol [36].
Chemical release of O‑glycans from solid phase
The resin was extensively washed with 1  M NaCl and 
DI (500  μL; 3×) after removal of N-glycans. Water was 
removed from the spin column by centrifuge (2000×g; 
30 s) and the resin was transferred to a 2-mL micro-cen-
trifuge tube. Two-hundred microlitre ammonia (NH4OH; 
26–28%) and 300  μL 500  mM PMP in methanol were 
mixed with resin, resulting in a lower concentration of 
ammonia (11.2%). The mixture was vortexed and reacted 
at 55  °C for 24–48  h (Fig.  1e). The samples were trans-
ferred back to the spin column to collect the superna-
tant. Resin was washed with DI water (300 μL; 3×) and 
all flow-through fractions were combined with the previ-
ously collected supernatant. After being dried under vac-
uum (Savant SpeedVac, Thermo Scientific), samples were 
re-suspended in 200 μL acidic water (1% acetic acid) and 
400 μL chloroform. The free PMP was completely mixed 
in chloroform while the labeled O-glycans were dissolved 
in 1% acetic acid. The excess PMP in chloroform was 
removed from the aqueous layer (water), and the extrac-
tion was repeated three more times (400 μL chloroform). 
The aqueous layer was dried under vacuum and re-dis-
solved in 1 mL of water (HPLC). The labeled O-glycans 
were purified using an SPE C18 cartridge, which was pre-
conditioned with 1 mL 100% acetonitrile (2×) and 1 mL 
water (3×). The C18-SPE-loaded samples were rinsed 
with 1 mL water (5×) and eluted with 200 μL 50% ace-
tonitrile (repeated once). The purified O-glycans were 
placed in a glass insert and dried under vacuum prior to 
LC–MS/MS analysis.
Mass spectrometry and data analysis
MALDI (matrix-assisted laser desorption/ionization) was 
performed using Shimadzu Resonance Maxima QIT-ToF. 
Laser energy was 140–160; 1 μL of DHB (2,5-dihydroxy-
benzoic acid)-DMA (dimethylaniline) was mixed with 1 μL 
of glycans. The modified glycans were cleaned by a C18-
SPE trap column (Thermo Scientific; Dionex nanoViper 
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Fingertight Fitting). Sample (12 μL) was injected to the trap 
column (C18) by the loading pump at a flow rate of 5 μL/
min. The nano-flow pump (Thermo Scientific; Dinoex 
UltiMate 3000) was set at a flow rate of 0.25 μL/min; the 
LC gradient was set from 4% (acetonitrile, 0.1% TFA) to 
50% within 70 min using an analytical column (Fisher Sci-
entific; Thermo Scientific Acclaim PepMap 100 C18). The 
full scan MS1 mass range was from 400 to 1800 Da (m/z) 
using positive mode (Thermo Scientific; Orbitrap Velos; 
collision-induced dissociation: 30%). The MS2 parameters 
were as follows: collision energy 29%, isolation width 2.0, 
m/z, activation time 0.2  ms, and HCD (high-energy col-
lision dissociation). Dynamic exclusion included repeat 
count 2, repeat duration 25 s, exclusion list size 500, and 
exclusion duration 5 s. Glycan spectra were analyzed using 
Thermo Xcalibur Qual Browser. Glycan composition was 
determined by (1) precursor matching and further con-
firmed by MS2 fragments (Additional file 1: Figure S1, 37 
MS/MS); and (2) database matching using CFG (http://
www.functionalglycomics.org), GlycomeDB (http://www.
glycome-db.org) and Glycosciences (http://www.glyco-
sciences.de/database/index.php) for those low abundance 
glycans. Glycans without MS/MS were given by their com-
position (N: HexNAc; H: Hexose; F: Fucose; S: NeuAc). 
The figures depicting the glycan structures were plotted 
using Glycoworkbench 2.1 software [53].
Results and discussion
GIG consists of three steps: (1) the denatured proteins 
are conjugated on a solid support (amine-reactive resin 
(aldehyde)) via reductive amination (Fig. 1a); the immo-
bilized proteins are modified via carbodiimide cou-
pling on the solid support for stabilization of the sialic 
acids (Fig.  1b); (2) N-glycans are released by PNGase 
F treatment (Fig.  1c) and labeled with isobaric tags 
(QUANTITY) for relative quantification [49] (Fig.  1d); 
(3) O-glycans are released from the solid support via 
β-elimination using ammonia in the presence of PMP 
(Fig. 1e). The labeled N-glycans and O-glycans are identi-
fied and quantified by LC–MS/MS.
Sequential release of N‑glycans and O‑glycans
To determine the performance of sequential release of 
N-and O-glycans from solid support, fetuin from bovine 
serum was conjugated on GIG resin to release glycans 
using PNGase F and ammonia. The first experiment 
was to determine the efficiency of N-glycan release by 
PNGase F, and then O-glycan release by β-elimination 
on the same sample. As shown in Fig. 2a, N-glycans are 
released directly from bovine fetuin conjugated on solid 
support by PNGase F digestion. The five major sialylated 
N-glycans are shown in Fig. 2a. Use the same specimen 
after N-glycan release, O-glycans were cleaved while 
their reducing-end alditols are protected by PMP [54]. 
The highly abundant O-glycans in fetuin include sia-
lylated O-GalNAc, i.e. NHS (DP7 was spiked as an inter-
nal standard) (Fig.  2b), which is in agreement with the 
results from recent chromatographic analysis [55]. These 
results indicate that N-glycans and O-glycans can be 
cleaved from their amino acid on the solid support.
Fig. 1 Schematic diagram of sequential releases and analyses of 
N-linked and O-linked glycans via chemoenzymatic method. a Immo-
bilize glycoproteins on solid support. b Modify sialic acids; c release 
N-glycans using PNGase F; d label N-glycans by the isobaric tags 
such as QUANTITY via reductive amination; e release O-glycans by 
β-elimination. The released O-glycans are purified using C18 cartridge 
and N-glycans are purified using Carbograph SPE column
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Protection of sialylated O‑glycans
The sialic acids are fragile and preferentially lost during 
sample preparation and ionization in MS. Sialic acid is 
negatively charged and hydrophilic, thus its identifica-
tion is ineffective in the positive ionization mode for MS. 
The negative ionization mode is commonly used and 
has been well developed for the analysis of intact sialic 
acids [56, 57]. Modification of sialic acid provides several 
advantages: (1) stabilization of sialic acids, (2) neutraliza-
tion of negative charge, and (3) enhanced hydrophobicity. 
Similar to modification on N-glycans [58], the sialic acid 
residues of O-glycans are simultaneously protected via 
carbodiimide coupling (Fig. 1b).
To demonstrate sialic acid modification on O-gly-
can analysis using GIG, mucin from bovine submaxil-
lary glands (MSB) was immobilized on resin using the 
detailed protocol described in our previous studies [14, 
36]. MALDI-MS profiling was used to compare the 
relative abundance of the sialylated O-glycans that are 
chemically released from MSB with sialic acid modi-
fication (Fig.  3a) and without modification (Fig.  3b). To 
estimate the signal between (a) and (b), an internal pep-
tide standard (Neurotensin, Sigma) was spiked in the 
MALDI matrix (20 μM/1 μL). The intensity of Neuroten-
sin is approximately the same (1000 mV) in (a) and (b). 
As shown in Fig. 3a, four major sialylated O-glycans are 
identified after sialic acid modification, including NS, 
NG, N2S, and N2G, which are listed in order of descend-
ing relative abundance. This result is consistent with find-
ings reported in the literature [31].
Analyses of N‑ and O‑glycans from ovarian cancer cells 
treated with O‑glycosylation inhibitor
We then applied the sequential release and analyses of N- 
and O-linked glycans from OVCAR-3 cells treated with 
Benzyl-α-GalNAc (BAG) to inhibit α-GalNAc biosynthe-
sis. Different concentrations of BAG (0 mM (control), 0.2, 
1, and 2 mM) were used to treat OVCAR-3 cells for 24 h. 
Cells were harvested and proteins were extracted. After 
protein (1 mg for each sample) immobilization, N-glycans 
were first released by PNGase F, followed by Carbograph 
cleanup [59]. One tenth of the N-glycans was loaded 
onto MALDI-MS for comparing the glycan profile from 
OVCAR-3 cells treated with different concentrations of 
BAG. An internal standard (25 μM/1 μL DP7) was used 
to determine the abundance of N-glycans as indicated in 
the Additional file  2: Table S1 (MALDI-OV3-Nglycan). 
Several observations are evident from the MALDI-MS 
analysis of N-glycans: (1) Oligomannoses are highly 
abundant N-glycans in OVCAR-3 cells; (2) Among the 
abundant oligomannose glycans, Man6 is the most abun-
dant compared to other oligomannose glycans; and (3) 
Most oligomannoses are upregulated in 0.2  mM BAG-
treated cells. The MALDI-MS profile of BAG-treated cell 
lines indicated that oligomannoses are highly abundant 
N-linked glycans in OVCAR-3 cells and affected by treat-
ments using different concentrations of BAG.
To quantify N-glycans, the released N-glycans were 
also labeled with 4-plex isobaric tags (QUANTITY) for 
quantitative analysis by ESI–MS (Thermo; Orbitrap Velos 
Mass Spectrometer) [49]. Figure  4 shows the MS/MS 
Fig. 2 Chemoenzymatic sequential releases of N-glycans and O-glycans from bovine serum-derived fetuin using GIG. a N-glycans were released by 
PNGase F on solid-phase; b O-glycans were released after N-glycans were released by mild β-elimination in 0.5 M PMP (1-phenyl-3-methyl-5-pyra-
zolone). The MS spectra was generated by MALDI
Page 6 of 11Yang et al. Clin Proteom  (2017) 14:3 
Fig. 3 Sialylated O-glycans of mucin from bovine submaxillary glands (MBS) by MALDI-MS. a The sialic acids that were stabilized by carbodiimide 
coupling have a significantly increased MS signal; b the sialic acids without modification have low intensity in MALDI-MS. An internal standard 
(Neurotensin, 20 μM/1 μL) was spiked in the sample. The sialic acid modified glycans have one sodium adduct [Na]+, while native glycans have an 
extra sodium adduct per sialic acid
Fig. 4 MS/MS fragmentation of QUANTITY-tagged N-glycans. The N4H5S2 was extracted from OVCAR-3 cells and labeled by QUANTITY. MS/MS was 
performed by Thermo Orbitrap Mass Spectrometer. When a reporter is lost, the mass is reduced by 176–178 with a “Loss reporter”
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fragmentation ions of N-glycans labeled with QUQNA-
ITY, from which the cartoon structure is determined. A 
total of 137 N-glycans were identified and the high abun-
dant N-glycans are highlighted in Fig. 5 and summarized in 
Additional file 2: Table S1 (LC-ESI-OV3-Nglycan). Among 
them, MS/MS spectra from the highest abundant glycans 
were generated (Additional file  1: Figure S1). After sialic 
acid labeling and reducing end tagging with QUANTITY, 
the hydrophobicity of N-glycans is significantly enhanced 
[50]. This allows the separation of the modified N-glycans 
on a C18 analytical column (15 cm in length) with the elu-
tion of oligomannoses first (Fig. 5a), followed by complex 
and highly sialylated N-glycans (Figs. 5b, c, d). Using a linear 
gradient from 4% ACN to 50% ACN over a 70 min period, 
the retention time is (a) 0–10 min for oligomannoses, (b) 
10–20 min for complex glycans, (c) 20–30 min for complex 
glycans with high-branch structures, and (d) 30–40  min 
for complex sialylated glycans. In general, N-glycans were 
upregulated in the BAG-treated cells. Quantitative analysis 
by QUANTITY shows that 35 N-glycans were significantly 
upregulated by BAG treatment at a concentration of 1 mM 
(Additional file 3: Table S2). 
The detail mechanism of N-glycan upregulation in 
BAG treated ovarian cancer cells is unclear. It has been 
indicated that the glycosylation of proteins in Golgi 
and in-transit glycoproteins could be affected by BAG 
[60]. Several polypeptide-N-acetyl-galactosaminyltrans-
ferases (ppGalNAcTs) are located throughout the Golgi, 
where N-glycans are synthesized. BAG inhibition could 
essentially affect many transcriptional factors that may 
regulate genes associated with N-glycan synthesis [61]. 
Therefore, the inhibition of O-GalNAc glycans might 
indirectly affect N-glycan biosynthesis [62].
BAG is a compound that acts as a competitive sub-
strate for the synthesis of core 1, core 2, core 3, and core 
4 O-GalNAc glycans in cells. It thus leads to a reduction 
in the synthesis of complex O-GalNAc glycans [29, 63]. 
The dominant O-glycans (26) are present in Table 1 (132 
Fig. 5 N-glycan profile of OVCAR-3 cells by LC–ESI–MS/MS. N-glycans were first released after sialic acid modification, and the released N-glycans 
were labeled using isobaric QUANTITY tags (Quaternary Amine Containing Isobaric Tag for Glycan). The labeled N-glycans were separated using a 
C18 analytical column (Thermo Scientific Acclaim PepMap, 15 cm). a Oligomannoses eluted from 0 to 10 min, b complex N-glycans eluted from 10 
to 20 min, c Complex N-glycans eluted from 20 to 30 min, and d complex and sialylated N-glycans eluted from 30 to 40 min
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Table 1 O-glycans identified from  OVCAR-3 cells treated with  the inhibitor Benzyl-α-GalNAc (BAG) using solid-phase 
chemoenzymatic method




(ratio to untreated cells)
Possible O-glycans
0mM 0.2mM 1mM 2mM
NS 2 932.4 512.9 1 0.722 1.028 0.639
N2H2 2 1079.4 749.0 1 0.799 1.130 0.830 
NHS 2 1094.5 675.0 1 0.672 0.593 0.677 
FN2H2 2 1225.5 895.1 1 0.704 0.817 0.716 
N2H3 2 1241.5 911.1 1 0.754 0.769 0.968 
FN3H3 2 1266.5 936.1 1 1.716 1.216 1.490 
F3NS 2 1370.5 951.1 1 0.819 1.118 1.487 
F2N2H2 2 1371.5 1041.1 1 0.906 0.657 0.871 
FN2H3 2 1387.5 1057.1 1 1.316 1.320 1.246 
N2H4 2 1403.5 1073.1 1 1.014 0.800 1.236 
N3H3 2 1444.6 1114.2 1 0.744 0.736 0.640 
N2H2S 2 1459.6 1040.1 1 1.020 1.198 0.850 
N3HS 2 1500.6 1081.1 1 0 0 0 
F3HS 2 1517.6 1098.1 1 2.658 0 4.026 
FN2H4 2 1549.6 1219.2 1 1.6 0.886 1.229 
FN2H2S 2 1605.6 1186.2 1 1.047 1.346 1.126 
FN2H5 2 1711.6 1381.2 1 1.853 1.618 1.912 
N2H6 2 1727.6 1397.2 1 0.910 1.015 0.959 
F3N2HS 2 1735.7 1316.2 1 1.617 0.827 1.358 
FN4H3 2 1793.7 1463.3 1 0.770 1.079 0.725 
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possible O-glycans were assigned using precursor match-
ing as described in the Additional file 4: Table S3). Based 
on the change of O-GalNAc glycans under different BAG 
concentrations, the abundance of eight O-GalNAc gly-
cans was reduced in BAG treated OVCAR-3 cells, includ-
ing NS, N2H2, NHS, FN2H2, F2N2H2, N3H3, FN3H2S and 
N2H2S. However, few O-GalNAc glycans (e.g., N3HS) 
shows negligibly reduced or even no change by BAG, 
suggesting their biosynthesis being affected by other fac-
tors (the complete list is given in the Additional file  4: 
Table S3). 
Mucin-type O-glycans are critically regulated in can-
cers. For example, when CA125, an ovarian cancer 
marker, purified from the spent media of OVCAR-3 
cells, O-glycomic analysis revealed that the sialylated 
O-glycans were highly abundant, containing NS, NHS 
and N2H2S; three dominant non-sialylated O-glycans 
were N2H2, N3H2, and N3H3 [64]. Our results indi-
cate that the sialylated O-glycans in OVCAR-3 cells are 
effectively inhibited by BAG; however, non-sialylated 
O-glycans remain minimally regulated by inhibition of 
O-glycan biosynthesis. These observations are consist-
ent with previous studies, indicating that BAG inhibition 
leads to a decrease of mucus secretion and a decreased 
intracellular amount of sialic acid [60, 63]. For example, 
BAG can impede the sialylation of O-glycosidic sugar 
chains on CD44, and the inhibition enhances experi-
mental metastatic capacity in melanoma cells [65]. Sub-
sequent studies have explored the possibility that the 
change of sialic acids in cells might be a consequence of 
the metabolic processing of BAG into Gal-BAG, which is 
a potent competitive inhibitor of the Gal-GalNAc-α2,3-
sialyltransferase [62, 66]. Further inhibition of O-GalNAc 
glycosylation can be achieved by increasing the concen-
tration of BAG (4–8  mM) and extending the treatment 
up to 72 h [61, 64, 67].
Conclusion
A streamlined approach is used for the systematic identi-
fication and quantification of N-linked and O-linked gly-
cans in the ovarian cancer cells. The performance of the 
platform is evaluated by the analysis of glycans in stand-
ard N- and O-linked glycoproteins. The stabilization of 
sialic acids by carbodiimide coupling to the solid support 
enhances the detection of sialylated glycans, which are 
not observed without sialic acid modification using in-
solution β-elimination.
Inhibition of ovarian cancer cells by an O-GalNAc-
targeted inhibitor appears to up-regulate N-glycans and 
down-regulate mucin-type O-glycans by two independ-
ent experiments using label-free glycomic analysis and 
isobaric labeled N-glycan analysis. To our knowledge, 
Table 1 continued
FN3H2S 2 1808.6 1389.2 1 0.565 0.826 0.783 
N4H4 2 1809.7 1479.3 1 1.373 1.940 0.602 
FN5H3 2 1996.8 1666.4 1 0.831 1.365 0.764 
FN4H2S 2 2011.7 1592.2 1 1.185 0 1.370 
N4H6 2 2133.8 1803.4 1 0.588 1.735 1.324 
FN6H3 2 2199.9 1869.5 1 0.827 1.358 1.346 




(ratio to untreated cells)
Possible O-glycans
0mM 0.2mM 1mM 2mM
BAG inhibitor was added to the cell medium for 24-h incubation before cell harvest. The concentration of BAG inhibitor is 0 (control), 0.2, 1, and 2 mM. F fucose, N 
HexNAc, H hexose, S Neu5Ac. (Standard deviation ≤10%) (The relative abundance is calculated by percentage of coverage from LC–MS/MS data)
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this is the first report to show the levels of N-glycans 
are regulated by O-linked glycosylation by O-GalNAc 
inhibitor. Even though the mechanism of this regula-
tion is unclear, results indicate that a low concentration 
of O-GalNAc inhibitor might favor the biosynthesis of 
N-glycans in OVCAR-3 cells. The regulation of glycosyla-
tion biosynthesis by drugs should include considerations 
of their effects on both N-linked and O-linked glycans.
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